SEC Form 4 · accession 0001104659-16-088407
Cardiff Oncology, Inc. · CRDF
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Erlander
Officer — Chief Scientific Officer
Period of report
Jan 4, 2016
Accepted (ET)
Jan 6, 2016 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001213037
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $5.18 | Jan 4, 2016 | A | 150,000 | A | — | Jan 4, 2026 | Common Stock | 150,000 | 725,000 | D |
Explanation of responses
- F13,125 of the stock options vest on a monthly basis over 48 months from date of grant.